Full Paper
round-bottomed flask equipped with a magnetic stir bar was
added [Rh(COD)Cl]2 (43 mg, 0.09 mmol) and DPPB (89 mg,
0.21 mmol). The reaction vessel was capped with a rubber septum
and was evacuated and refilled with nitrogen gas. DCE (3.5 mL)
was added via syringe, followed by 5-phenyl-1-pentyne (0.52 mL,
3.47 mmol). Pinacol borane (1.5 mL, 10.41 mmol) was then added
dropwise via syringe. The resulting solution was allowed to stir at
room temperature for 24 h. The reaction was diluted with Et2O and
was then filtered through a pad of silica. The filtrate was concen-
trated in vacuo and purified by flash silica column chromatography
(EtOAc/hexanes, 5:95) to give the desired product as a yellow oil.
1H NMR (400 MHz, CDCl3): d=7.23–7.19 (m, 2H), 7.14–7.10 (m, 3H),
2.59 (t, J=7.6 Hz, 2H), 1.52–1.61 (m, 4H), 1.26–1.34 (m, 2H), 1.21 (s,
12H), 1.20 (s, 12H), 0.72 ppm (t, J=7.9 Hz, 1H). Full characteriza-
tion data is available in ref. [6b].
7.1 Hz, 2H), 7.47 (d, J=7.2 Hz, 2H), 7.42 (d, J=7.1 Hz, 2H), 7.32–
7.16 (m, 12H), 5.17 (dd, J=8.6, 3.6 Hz, 1H), 4.74 (d, J=8.5 Hz, 2H),
3.24 (m, 4H), 1.32 (s, 3H), 1.15 (t, J=7.1 Hz, 6H), 0.27 ppm (s, 3H);
13C NMR (125 MHz, CDCl3): d=147.3, 146.7, 142.5, 141.9, 129.1,
128.8, 128.8, 128.0, 127.6, 127.4, 127.3, 127.2, 127.2, 127.1, 127.1,
127.0, 126.9, 111.4, 82.6, 82.6, 82.4, 82.2, 81.5, 81.2, 81.2, 39.0, 38.8,
27.6, 25.3, 15.3, 15.2 ppm; 31P NMR (162 MHz, CDCl3): d=
141.4 ppm; IR (microscope; CHCl3): v˜ =3089, 3040, 2970, 2932,
2869, 1447, 1381, 1215, 1028, 917, 823, 758 cmÀ1; HRMS (ESI) for
C35H39NO4P [M+H]+: calcd: 568.2611; found: 568.2604; [a]2D0
À132.77 (c=0.35, CHCl3); m.p. 149–1518C.
=
(3aR,8aR)-N,N-Diisopropyl-2,2-dimethyl-4,4,8,8-tetraphenyltetra-
hydro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepin-6-amine (L16):
1H NMR (400 MHz, CDCl3): d=7.82 (d, J=8.1 Hz, 2H), 7.63 (d, J=
8.0 Hz, 2H), 7.47 (d, J=7.2 Hz, 2H), 7.44 (d, J=7.2 Hz, 2H), 7.31–
7.14 (m, 12H), 5.19 (dd, J=8.6, 3.8 Hz, 1H), 4.62 (d, J=8.6 Hz, 1H),
3.98 (sep, J=6.2 Hz, 2H), 1.42 (s, 3H), 1.24 (d, J=6.8 Hz, 6H), 1.20
(d, J=6.8 Hz, 6H), 0.24 ppm (s, 3H); 13C NMR (125 MHz, CDCl3): d=
147.5, 147.0, 142.9, 142.1, 129.1, 128.7, 128.7, 127.8, 127.4, 127.3,
127.1, 127.1, 127.1, 126.9, 126.8, 111.0, 83.1, 83.1, 82.6, 82.4, 81.1,
81.1, 80.7, 80.7, 44.3, 44.2, 27.8, 25.0, 24.4, 24.3, 24.2, 24.1 ppm;
31P NMR (162 MHz, CDCl3): d=140.4 ppm; IR (microscope, CHCl3):
v˜ =3089, 3025, 2967, 2933, 2903, 1395, 1216, 1183, 1003, 981, 878,
736 cmÀ1; HRMS (ESI) for C37H43NO4P [M+H]+: calcd: 596.2924;
found: 596.2924; [a]2D0 =À96.64 (c=0.82, CHCl3); m.p. 135–1388C.
(2R,6S)-2,6-Dimethyl-1-((3aR,8aR)-4,4,8,8-tetrakis(4-isopropyl-
phenyl)-2,2-dimethyltetrahydro-[1,3]dioxolo[4,5-e][1,3,2]dioxa-
phosphepin-6-yl)piperidine (L31): 1H NMR (400 MHz, CDCl3): d=
7.71 (d, J = 8.5 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz,
2H), 7.32 (d, J = 8.4 Hz, 2H), 7.14–7.10 (m, 6H), 7.07 (d, J =8.3 Hz,
2H), 5.12 (dd, J = 8.6, 3.6 Hz, 1H), 4.60 (d, J = 8.5 Hz, 1H), 4.11–
4.03 (m, 2H), 2.91–2.79 (m, 4H), 1.98–1.84 (m, 1H), 1.79–1.64 (m,
2H), 1.61–1.49 (m, 3H), 1.39 (s, 3H), 1.38 (d, J = 7.9 Hz, 3H), 1.31
(d, J = 7.1 Hz, 3H), 1.24–1.21 (m, 21H), 1.17 (dd, J = 6.9, 2.0 Hz,
9H), 0.19 ppm (s, 3H); 13C NMR (125 MHz, CDCl3): d=147.4, 147.3,
147.1, 146.8, 145.0, 144.5, 140.2, 139.6, 129.0, 128.4, 127.0, 126.9,
125.9, 125.6, 125.4, 125.0, 110.9, 83.2, 83.2, 82.8, 82.6, 81.0, 80.9,
80.6, 46.4, 46.2, 45.9, 45.7, 33.6, 33.6, 33.5, 33.5, 31.6, 31.4, 27.7,
24.9, 24.0, 23.9, 23.9, 23.8, 14.8 ppm; 31P NMR (162 MHz, CDCl3):
d=139.1 ppm; IR (microscope, CHCl3): v˜ =2961, 2931, 2870, 1510,
2,2’-(3-Phenylpropane-1,1-diyl)bis(4,4,5,5-tetramethyl-1,3,2-diox-
aborolane) (13): The title compound was prepared according to
the literature procedure[8a] with slight modifications. To a 25 mL
round-bottomed flask equipped with a magnetic stir bar was
added CuI (19.2 mg, 0.10 mmol), B2pin2 (508 mg, 2.00 mmol), PPh3
(34.4 mg, 0.13 mmol) and LiOMe (114 mg, 3 mmol). The reaction
vessel was capped with a rubber septum and was evacuated and
refilled with nitrogen gas. A solution of (3,3-dibromopropyl)ben-
zene prepared according to literature procedure[15] (278 mg,
1.00 mmol) in DMF was added via syringe. The resulting solution
was allowed to stir at room temperature for 24 h. The reaction was
then diluted with Et2O (6 mL) and filtered through a plug of Celite.
The filtrate was washed with water (310 mL) and dried over
MgSO4(s), filtered, then concentrated in vacuo. The crude mixture
was purified flash silica column chromatography (1–5% EtOAc/hex-
1
anes) to give the desired product as a white solid (75%). H NMR
(400 MHz, CDCl3): d=7.23–7.19 (m, 2H), 7.15–7.08 (m, 3H), 2.56 (t,
J=7.9 Hz, 2H), 1.82 (q, J=7.9 Hz, 2H), 1.20 (s, 12H), 1.20 (s, 12H),
0.78 ppm (t, J=7.9 Hz, 1H). Full characterization data are available
in ref. [8a].
General procedure for the synthesis of TADDOL-derived
phosphoramidites
All phosphoramidites were synthesized according to literature pro-
cedure[7b] with slight modification. To a 25 mL round-bottomed
flask equipped with a magnetic stir bar was added the diol
(0.60 mmol). THF (3 mL) followed by Et3N (0.29 mL, 0.95 mmol)
were added via syringe, and the resulting solution was cooled to
08C before the dropwise addition of phosphorous trichloride
(58 mL, 0.66 mmol). The reaction mixture was stirred for 1 h and
the amine (2.70 mmol) was then slowly added at 08C. The reaction
was warmed to room temperature and stirred, overnight. The reac-
tion was then diluted with Et2O (15 mL) and filtered through a pad
of Celite. The filtrate was concentrated in vacuo and the resulting
crude mixture was purified by flash silica column chromatography
(0–2%EtOAc/1% Et3N/hexanes).
1215, 1020, 1002, 842, 812, 781, 758 cmÀ1
; HRMS (ESI) for
C50H67NO4P [M+H]+: calcd: 776.4802; found: 776.4789; [a]2D0
À92.71 (c = 0.41, CHCl3); m.p. 116–1208C.
=
Acknowledgements
This research was generously funded by the Natural Science
and Engineering Research Council of Canada, and the Universi-
ty of Alberta. H.-Y.S. was supported by a NSERC Canada Gradu-
ate Scholarship-D and an Alberta Innovates Health Solutions
Studentship. K.K. thanks the Japan Society for the Promotion
of Science (JSPS) for scholarship support allowing a research
exchange at the University of Alberta.
(3aR,8aR)-N,N,2,2-Tetramethyl-4,4,8,8-tetra-p-tolyltetrahydro-
[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepin-6-amine (L1): 1H NMR
(400 MHz, CDCl3): d=7.62 (d, J=8.3 Hz, 2H), 7.46 (d, J=8.2 Hz,
2H), 7.34 (d, J=8.3 Hz, 2H), 7.29 (d, J=8.2 Hz, 2H), 7.12–7.07 (m,
6H), 7.04 (d, J=8.0 Hz, 2H), 5.12 (dd, J=8.4, 3.2 Hz, 1H), 4.77 (d,
J=8.5 Hz, 1H), 2.74 (s, 3H), 2.71 (s, 3H), 2.31 (s, 3H), 2.30 (s, 6H),
2.27 (s, 3H), 1.30 (s, 3H), 0.31 ppm (s, 3H). Full characterization
data are available in ref. [8a].
Keywords: catalysis
·
cross-coupling
·
organoboron
·
palladium · stereoselectivity
(3aR,8aR)-N,N-Diethyl-2,2-dimethyl-4,4,8,8-tetraphenyltetrahy-
[2] a) J. C. H. Lee, D. G. Hall, in Metal-Catalyzed Cross-Coupling Reactions and
More, Vol. 1 (Eds.: A. de Meijere, S. Bräse, M. Oestreich), Wiley-VCH,
Weinheim, 2014, Chapter 2, pp. 65–132; b) A. J. J. Lennox, G. C. Lloyd-
dro-[1,3]dioxolo[4,5-e][1,3,2]dioxaphosphepin-6-amine
(L15):
1H NMR (400 MHz, CDCl3): d=7.77 (d, J=7.1 Hz, 2H), 7.60 (d, J=
Chem. Eur. J. 2015, 21, 19186 – 19194
19193
ꢀ 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim